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Abstract
Background—In April 2012, the Jordan Ministry of Health investigated an outbreak of lower 
respiratory illnesses at a hospital in Jordan; 2 fatal cases were retrospectively confirmed by real-
time reverse transcription polymerase chain reaction (rRT-PCR) to be the first detected cases of 
Middle East respiratory syndrome (MERS-CoV).
Methods—Epidemiologic and clinical characteristics of selected potential cases were assessed 
through serum blood specimens, medical record reviews, and interviews with surviving outbreak 
members, household contacts, and healthcare personnel. Cases of MERS-CoV infection were 
identified using 3 US Centers for Disease Control and Prevention serologic tests for detection of 
anti–MERS-CoV antibodies.
Results—Specimens and interviews were obtained from 124 subjects. Seven previously 
unconfirmed individuals tested positive for anti–MERS-CoV antibodies by at least 2 of 3 serologic 
tests, in addition to 2 fatal cases identified by rRT-PCR. The case-fatality rate among the 9 total 
cases was 22%. Six subjects were healthcare workers at the outbreak hospital, yielding an attack 
rate of 10% among potentially exposed outbreak hospital personnel. There was no evidence of 
MERS-CoV transmission at 2 transfer hospitals having acceptable infection control practices.
Conclusions—Novel serologic tests allowed for the detection of otherwise unrecognized cases 
of MERS-CoV infection among contacts in a Jordanian hospital-associated respiratory illness 
outbreak in April 2012, resulting in a total of 9 test-positive cases. Serologic results suggest that 
further spread of this outbreak to transfer hospitals did not occur. Most subjects had no major, 
underlying medical conditions; none were on hemodialysis. Our observed case-fatality rate was 
lower than has been reported from outbreaks elsewhere.
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In April 2012, the Jordan Ministry of Health (JMoH) investigated a cluster of 13 suspected 
pneumonia cases among healthcare personnel, of which 2 were fatal, at a hospital in the city 
of Zarqa [1]. Despite testing for multiple potential pathogens, the investigation did not 
identify a known etiology for these infections. Following the discovery of Middle East 
respiratory syndrome coronavirus (MERS-CoV) in September 2012 [2], specimens from the 
2 fatal cases in Jordan were retrospectively tested and both yielded positive results for 
MERS-CoV by real-time reverse transcription polymerase chain reaction (rRT-PCR), and 
were reported to the World Health Organization (WHO). These were the first confirmed 
human cases of infection with this emergent virus, which continues to appear as sporadic 
cases and clusters internationally, and which is now the focus of worldwide public health 
investigation and response [3, 4].
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Using newly developed serologic assays to determine MERS-CoV antibody responses 
among case contacts in this outbreak, epidemiologists from the JMoH, US Centers for 
Disease Control and Prevention (CDC), and regional partners conducted a retrospective 
seroepidemiologic investigation to (1) confirm whether surviving outbreak members had 
presence of antibodies to MERS-CoV, (2) ascertain whether viral transmission occurred 
among household contacts or to other healthcare personnel, and (3) describe the clinical 
features of all detected MERS-CoV infections in Jordan.
METHODS
Epidemiologic Investigation Methods
We interviewed and collected serum specimens from available members of the initial 
outbreak (who were admitted to the focal outbreak hospital during the period from 15 March 
to 30 April 2012 with fever and dry cough, and with radiological evidence of pneumonia), 
their household contacts (who reported usually sleeping under the same roof as a defined 
outbreak member during February–April 2012), a sample of healthcare personnel from 3 
medical institutions that admitted outbreak subjects (nonsystematic enrollment, with 
preference toward those reporting close contact with outbreak members), and field 
investigators from the JMoH. Hospitalized subjects meeting the initial outbreak case 
definition were subsequently transferred from the focal outbreak hospital to 2 other hospitals 
in Amman. Participating healthcare personnel were employed at one of these hospitals or at 
JMoH during February–April 2012.
Epidemiologic data were obtained through medical record reviews and personal interviews 
during our May 2013 investigation. Interviews were conducted in Arabic, and documented 
contact history (with outbreak members, household members, visiting travelers, and 
animals) and occupational exposures. We conducted medical record reviews and key 
informant interviews with clinicians who provided medical care to patients with suspected 
infection and heads of infection control units at each medical institution and at the JMoH. 
Informed consent was obtained prior to serum collection and interviews. As a public health 
response to a disease outbreak, this investigation did not require institutional review board 
review.
Laboratory Investigation Methods
All work with live MERS-CoV was done in CDC Biosafety Level 3 (BSL-3) containment 
facilities in Atlanta, Georgia. Serum samples were inactivated using 2 × 106 rads γ-
irradiation and stored at −80°C until use.
To maximize specificity, we defined MERS-CoV antibody positivity as subjects having 
correlated, positive laboratory results from the HKU5.2N screening enzyme-linked 
immunosorbent assay (ELISA), as well as confirmed positive results by either the MERS-
CoV immunofluorescence assay (IFA) or the MERS-CoV microneutralization assay (MNT) 
(Supplementary Table 1). An initial indeterminate test result was recorded for those subjects 
having only a single, uncorrelated positive test result.
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Antibody Detection by HKU5.2 Nucleocapsid ELISA and MERS-CoV IFA and MNT
Genetic sequencing data indicate that MERS-CoV is a β-coronavirus (subgroup 2c) similar 
to the bat CoVs HKU4 and HKU5. The recombinant btHKU5.2 nucleocapsid protein– based 
ELISA was developed by the CDC to detect the presence of antibodies that cross-react with 
the HKU5.2 N protein in serum samples from possible MERS cases. If cross-reactive 
antibodies were detected in serum samples, then confirmation of MERS-specific antibodies 
was determined by either MERS-CoV MNT or IFA. Pi-BatCoV HKU5.2 nucleocapsid (N) 
gene in pET-28b (+) plasmid was provided by Dr Susanna Lau, University of Hong Kong. 
His-tagged recombinant protein was expressed in Escherichia coli and purified by metal 
affinity chromatography. Recombinant HKU5.2N protein indirect ELISA was developed 
using a modified version of the severe acute respiratory syndrome (SARS) CoV N ELISA 
described by Haynes et al [5]. Sera were considered positive when the optical density (OD) 
values were at or above the 0.43 cutoff value (mean absorbance at 405 nm of sera from US 
blood donors plus 3 standard deviations). The overall specificity of the assay was determined 
after screening 545 serum samples from donors in the United States and the Middle East and 
persons with other non-MERS respiratory infections (eg, human coronavirus [hCoV] OC43, 
hCoV-229E, SARS-CoV, hCoV-NL63, rhinovirus, human metapneumovirus, H1N1). The 
assay specificity was 96.7% (527/545). Serum from HKU1 human serum was not available 
for evaluation; however, HKU1 mouse hyperimmune serum did not cross-react with the 
HKU5.2 N protein. At a screening dilution of 1:400, sera with OD values at or near the 
cutoff were titered with serial 4-fold dilutions (1:100–1:6400) and further evaluated using 
MERS-CoV (Hu/Jordan-N3/2012) (GenBank KC776174.1) IFA and MNT.
MERS-CoV Immunofluorescence
Indirect immunofluorescence was performed by screening sera at a dilution of 1:50 or 1:100 
on paraformaldehyde-fixed, acetone-methanol–permeabilized, MERS-CoV–infected or – 
uninfected control Vero cells. The source of the positive control for this assay was a serum 
sample from a patient infected with MERS-CoV Hu/England-N1/2012 (provided by M. 
Zambon, Public Health England). Antihuman immunoglobulin (Ig) G, IgM, and IgA 
fluorescein isothiocyanate conjugate was used and specific fluorescence was detected under 
an immunofluorescence microscope. A positive result was scored when fluorescent intensity 
equaled or was higher than that of the positive control. A weakly positive result was scored 
when fluorescent intensity was lower than that of the positive control.
MERS-CoV Microneutralization
Serum samples were tested for the presence of neutralizing antibodies to MERS-CoV using 
a modified MNT method described for SARS-CoV [6]. The neutralization titer was 
measured as the reciprocal of the highest serum dilution that completely inhibited Vero cell 
monolayer lysis in at least 1 of the 3 triplicate wells. Controls were included for each MNT 
assay performed, including the input virus back titration and mock-infected cells. All assay 
results were confirmed in 3 separate assays, and representative data are presented.
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Statistical Methods
Tests of statistical significance were performed between the MERS-CoV antibody–positive 
and –negative subjects, including Fisher exact test and χ2 tests for categorical variables using 
SAS software version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
Serologic specimens and interviews were obtained from 124 subjects. We obtained serologic 
specimens and data from 9 of the 11 (82%) surviving members meeting the initial outbreak 
case definition; the remaining 2 subjects were unable to be interviewed (1 member was lost 
to follow-up and 1 did not consent) (Figure 1). We also enrolled 26 household contacts and 
89 subjects who did not meet the initial outbreak case definition who worked in healthcare 
and allied professions. Among the healthcare personnel interviewed, 58% were nurses, 21% 
were physicians, and the remaining were allied health professionals; approximately half 
were employed at the focal outbreak hospital.
Seven of the 124 subjects tested positive for anti-MERS-CoV antibodies by both HKU5.2 
ELISA and IFA (Table 1 and Supplementary Figure 1), and all but 1 also had detectable 
neutralizing antibody titers as determined by MNT. The subject who did not have detectable 
neutralizing antibodies was test-positive both by HKU5.2N ELISA and by a confirmative 
IFA. Demographic and epidemiologic comparisons of seropositive and seronegative subjects 
are provided in Supplementary Table 2.
Sera from the 2 fatal cases (designated outbreak subjects 01 and 12) having positive rRT-
PCR tests were also tested by the 3 described serology tests. A serum sample from outbreak 
subject 01 (taken 16 days after onset of respiratory symptoms) was positive by HKU5.2N 
ELISA and IFA and had detectable MERS-CoV neutralizing antibodies. Two serum 
specimens from outbreak subject 12 (collected 26 and 32 days after onset) were negative for 
anti–MERS-CoV antibodies.
Of the 7 subjects found to be positive for anti–MERS-CoV antibodies during this 
investigation, 6 were surviving members of the initial outbreak group and 1 was previously 
unrecognized. Thus, including the 2 fatal cases previously detected and reported, a total of 9 
individuals in this outbreak had evidence of MERS-CoV infections by acute rRT-PCR tests 
(n = 2) or convalescent antibody tests (n = 7). The case-fatality rate among all test-positive 
subjects was 22% (2 of 9). We documented that each serologic test–positive subject had 
unprotected MERS-CoV exposure(s) to at least 1 rRT-PCR test-positive subject. An 
additional 8 subjects had single positive test results by either HKU5.2N ELISA or IFA, but 
their MERS-CoV antibody status was considered indeterminate because both tests were not 
positive (Table 1).
Healthcare Personnel
We obtained specimens and data from a total of 97 healthcare personnel who worked during 
February–April, 2012, representing a majority of intensive care (intensive care unit [ICU] 
and coronary care unit [CCU]) personnel at the outbreak hospital as well as other personnel 
having close contact with initial outbreak investigation members (Figure 1). These included 
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8 surviving outbreak members who were healthcare personnel at the focal outbreak hospital 
and were not lost to follow-up, 49 other personnel at the focal outbreak hospital, 16 
personnel at transfer hospital A, 20 personnel at transfer hospital B, and JMoH’s 4 outbreak 
investigators. Of the 57 healthcare personnel at the focal outbreak hospital who survived and 
the 1 who died, 6 (10%) had cases of MERS-CoV. Our investigation provided no evidence of 
MERS-CoV infections or transmission events among personnel at the 2 receiving transfer 
hospitals, even though some patients were transferred temporally close to their symptom 
onset dates. Interviews with surviving subjects and family members revealed that 
transmission opportunities among healthcare personnel were not restricted to the workplace.
Household Contacts
We obtained serologic specimens from members of 11 households, including those from the 
initial outbreak group and another 26 subjects who had resided in those outbreak member 
households during the outbreak period. One household was lost to follow-up, and 1 did not 
consent for participation. From one of these households was the symptomatic wife of an 
initial outbreak investigation member who tested positive for MERS-CoV antibodies. 
Twelve household subjects were children <18 years old, all of whom were serologically test 
negative.
Summary of Underlying Conditions, Symptoms, and Clinical Findings
A summary of underlying conditions for test-positive subjects, including the 2 fatal cases 
initially identified by rRT-PCR (outbreak members 01 and 12), is presented in Table 2. Of 
the 9 test-positive subjects, 66% were male, with a median age of 40 years (range, 25–60 
years) at illness onset. We found no evidence of underlying immunodeficiency or 
immunosuppressant medications/therapies among any of these subjects. One subject had an 
atrial septal defect, 2 had a history of hypertension, 2 were smokers at the time of illness, 
and 1 reported a pregnancy of 5 months’ gestation. Although diabetes mellitus has been 
observed as a potential risk factor for MERS-CoV [7], none of the subjects reported here had 
a prior diagnosis of diabetes mellitus and, based on serum glucose values taken during their 
hospitalizations, none had indications of undiagnosed diabetes mellitus.
The most common presenting symptoms, as documented in medical charts, included fever 
(89%), cough (89%), dyspnea (56%), chest pain (44%), and malaise (33%). Eight subjects 
presented for hospital care a median of 5 days after symptom onset (range, 1–14 days). Of 
these patients, 7 (88%) had cough, 7 (88%) had documented fever (temperature (≥38.0°C), 6 
(75%) had dyspnea, 5 (63%) had chest pain, and 5 (63%) had malaise at some point during 
their disease course. Less common symptoms included chills (38%), wheezing (25%), and 
diarrhea, vomiting, sore throat, palpitations, and confusion (13% each).
Seven subjects had abnormal chest radiographic findings reported within 3 days of 
presentation, and 3 of those 7 had bilateral findings. Of the remaining 4 subjects with initial 
unilateral findings, 3 went on to develop bilateral infiltrates later in their hospitalization, 
documented either by chest radiography or computed tomography (CT). One subject 
(outbreak member 12) received an initial diagnosis of pericarditis, and a CT scan with 
abnormal pulmonary findings was reported 4 days later (Table 3).
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Seven of the 8 subjects (88%) who presented to medical care were admitted; 1 refused 
admission. Six subjects (75%) required respiratory support with at least supplemental 
oxygen, and 4 subjects (50%) received intensive care (in CCU or ICU), but only the 2 (25%) 
patients who died required mechanical ventilation, of which 1 patient also required pressor 
support (dopamine and norepinephrine) for cardiorespiratory failure. Complications among 
hospitalized subjects were also limited to the 2 patients who died, 1 of whom had 
hyperkalemia with associated ventricular tachycardia, disseminated intravascular 
coagulation, and eventual cardiac arrest; the other had pericarditis, pericardial and pleural 
effusions, and supraventricular tachycardia late in the course of illness.
Although leukopenia (<4.0 × 109/L) was observed in 2 subjects, lymphopenia (<1.5 × 109/L) 
was observed in 6 of the 7 subjects who had documented complete blood counts with 
differentials (86%). Elevated leukocyte counts (>11 × 109/L) were observed during the 
course for 2 subjects (25%), both of whom died. These 2 subjects also had laboratory 
abnormalities consistent with multiorgan system failure late in the course of disease. These 
included evidence of elevated alanine aminotransferase and aspartate aminotransferase (>40 
U/L) and significant coagulopathy with an international normalized ratio of >1.5, as well as 
thrombocytopenia (<140 × 109/L). In addition, the 2 subjects who died had elevated serum 
creatinine measurements (≥133 μmol/L) on the day of their deaths. A third case had an 
isolated elevated creatinine measurement, but had a subsequent normal value the following 
day. No patient received hemodialysis (Table 3).
Outbreak member 01 died 17 days after onset of symptoms (on day 11 of hospitalization) 
and outbreak member 12 died 35 days after onset of symptoms (on day 22 of 
hospitalization). The remaining 7 subjects survived, and the 5 who were hospitalized were 
discharged following a median of 8 days (range, 4–16 days). Despite having respiratory 
symptoms, the pregnant household subject did not seek medical care due to concerns 
regarding receiving chest radiography and medications. This pregnancy resulted in stillbirth 
during the course of her illness [8].
Surviving subjects and the family members of deceased patients reported that contact with 
animals was rare in this urbanized area, and no contact with camels was identified among 
subjects having early symptom onsets. Furthermore, none of the subjects had traveled to, or 
had received visitors from, the Arabian Peninsula shortly prior to symptom onset.
Infection Control
At the focal outbreak hospital, there were no physical barriers between CCU and ICU beds, 
spaced approximately 3 meters, with the exception of cloth drapes in the CCU. Isolation or 
negative-pressure rooms were not present, and infection control compliance issues were 
reported during the outbreak. Infection control insufficiencies were not noted at the 2 
receiving transfer hospitals.
DISCUSSION
We used novel serologic assays to determine antibody responses of subjects from a MERS-
CoV outbreak investigation in Jordan, including the earliest cases of this emerging virus yet 
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discovered. In addition to 2 fatal cases confirmed by rRT-PCR and reported to WHO, we 
discovered 7 previously unconfirmed and unreported MERS-CoV infections. Detection of 
these 7 additional antibody-positive subjects, including healthcare personnel from the focal 
outbreak hospital and a family contact of 1 antibody-positive subject, and the establishment 
of contacts with MERS-CoV infected subjects when potentially infectious, suggests that 
human-to-human transmission of MERS-CoV occurred. Although community exposures 
were possible, healthcare-associated transmission was a plausible explanation for healthcare 
personnel infections. MERS-CoV infections were not detected among healthcare personnel 
at a transfer hospital having better adherence to infection control measures.
Compared with published descriptions of Saudi Arabian and French cases [9–12], among the 
9 total Jordanian cases identified through our collaborative investigation, subjects were 
younger and had fewer underlying medical conditions, and there was a lower case-fatality 
rate. Although all subjects with MERS-CoV infection in our investigation had acute 
respiratory illnesses during the outbreak period, 78% of those who were infected survived. 
Most subjects had no underlying medical conditions and none were on hemodialysis or had 
indications of diabetes mellitus. One newly detected subject, who was a household contact, 
did not seek medical care. Our data support the probability that, in outbreak settings, 
infections may remain undetected among subjects who have mild symptoms, lack 
predisposing conditions, or have barriers to accessing appropriate diagnostic care. Therefore, 
the true MERS-CoV case-fatality rate may be lower than that based on symptomatic, 
hospitalized cases alone.
The presenting symptoms we observed were largely consistent with those of previously 
described MERS-CoV cases [13–16] and included fever with respiratory symptoms such as 
cough and dyspnea, and associated infiltrates on chest radiography. On initial presentation, 
many subjects did not have evidence of bilateral pneumonia. Although gastrointestinal 
symptoms such as vomiting and diarrhea were documented for 2 subjects, we did not 
observe these as presenting symptoms, as they were in Saudi Arabian and French cases. 
Once hospitalized, lymphopenia, a prominent laboratory feature among previously described 
cases, was observed in the majority of our subjects. However, other laboratory abnormalities 
observed in previous reports, such as thrombocytopenia, were limited mostly to the 2 fatal 
cases late in the course of illness, consistent with multiorgan system failure. Also, unlike 
previously reported cases, renal failure was not a prominent clinical feature among our 
subjects, as renal dysfunction was observed only in the 2 fatal cases on the day of death.
Rapid isolation of patients with suspected MERS-CoV and rigorous infection control 
practices at the receiving transfer hospitals may have been important in preventing 
transmission at these locations. Hospitals should have established policies and procedures 
for the rapid identification of suspected or known MERS-CoV cases and implementation of 
appropriate infection prevention measures. The CDC recommends standard, contact, and 
airborne precautions for the management of hospitalized patients with known or suspected 
MERS-CoV infection [17].
One Jordanian patient was initially hospitalized with pericarditis, a manifestation similar to 
1 MERS-CoV case occurring in the Kingdom of Saudi Arabia [9]. Although this Jordanian 
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patient’s serologic specimens tested negative for MERS-CoV antibodies at periods 
throughout his hospital stay, 1 acute specimen collected several days before death was 
confirmed positive for the virus by rRT-PCR. These laboratory findings and the patient’s 
exposure in the CCU, where he was situated in the bed directly next to another patient with 
rRT-PCR–confirmed MERS-CoV, collectively suggest the likelihood that the patient was 
nosocomially infected with MERS-CoV and died before an antibody response was 
detectable.
Based on the knowledge of SARS-CoV antibody responses, IgG and neutralizing antibodies 
to SARS-CoV peaked 4 months following a patient’s recovery from acute infection [18]. 
Antibody levels did decline over time, but detectable SARS-CoV neutralizing antibodies 
persisted up to 2 years after onset of SARS-CoV symptoms [19, 20]. Approximately 13 
months had passed between our May 2013 investigation and the April 2012 outbreak. 
Although this was sufficient time for infected subjects to produce an antibody response to 
MERS-CoV, the role of waning immunity on the antibody response [21] and whether 
persistence of these antibodies is important for protection from reinfection remain unclear.
We implemented a rigorous case definition based on an ELISA-positive result plus at least 1 
correlating assay result to maximize specificity. Infections with SARS-CoV triggered 
humoral and cellular immune responses in all studied humans [22], and high titers of 
neutralizing antibodies were observed in response to SARS-CoV infections, but such 
characteristics of the MERS-CoV immunologic response remain unknown. As for those 
indeterminate laboratory findings among subjects with documented MERS-CoV exposure(s) 
but having only an ELISA-positive result and mild or absent respiratory symptoms, it is 
possible that the viral exposure to these subjects did not trigger a long-lasting IFA- or MNT-
recognizable immune response.
Because obtaining appropriate lower respiratory specimens from subjects having mild or 
asymptomatic infections is challenging, the use of serologic assays to identify otherwise 
undetected cases of MERS-CoV has been demonstrated to be a useful tool. Serological 
surveys have been conducted in retrospective case investigations around instances of MERS-
CoV importations in Europe [23], as well as for establishing estimates of MERS-CoV 
seroprevalence among populations at risk [24]. Further validation of serologic assays and 
assessments of how they complement rRT-PCR testing is needed.
Our investigation was unable to find evidence of any exposure (either zoonotic contacts, 
human contacts from the Arabian Peninsula, or among hospitalized contacts preceding the 
earliest symptomatic cases) that might explain the origin of the virus. The precise route(s) of 
MERS-CoV transmission remains unclear overall, but several MERS-CoV sequences have 
been identified in dromedary camel nasal secretions, including one that is indistinguishable 
from that found in infected humans [25].
In conclusion, the Jordan respiratory illness outbreak in April 2012 resulted in a total of 9 
test-positive MERS-CoV subjects. The source of the virus in these earliest known MERS-
CoV cases remains unknown. Compared with other reports, the improved survivability we 
observed is perhaps related to the youth and relative lack of underlying illnesses among the 
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subjects we investigated. Infection control practices at both transfer receiving hospitals may 
have been important in preventing MERS-CoV transmission in those facilities. Since the 
discovery of the MERS-CoV, enhanced surveillance for severe acute respiratory illnesses in 
Jordan has been implemented. International severe acute respiratory infection surveillance, 
collaborative investigations, and vigilance among healthcare providers are necessary 
components for addressing and preventing the further spread of MERS-CoV worldwide.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Venn diagram of numbers of subjects in the Middle East respiratory syndrome coronavirus 
(MERS-CoV) investigation. *Tested positive by serologic antibody and/or real-time reverse 
transcription polymerase chain reaction.
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